Loading...

Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.

The aromatase inhibitor, 'pyridoglutethimide' (PyG), has been shown previously to suppress serum oestrogen levels in postmenopausal breast cancer patients and to achieve clinical responses at a dose of 500 mg twice daily (b.d.). This report gives the results of a detailed pharmacokinetic a...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Dowsett, M., MacNeill, F., Mehta, A., Newton, C., Haynes, B., Jones, A., Jarman, M., Lonning, P., Powles, T. J., Coombes, R. C.
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 1991
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977449/
https://ncbi.nlm.nih.gov/pubmed/1931611
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!